The latest price target for Tourmaline Bio (NASDAQ:TRML) was reported by Guggenheim on December 11, 2024. The analyst firm set a price target for $0.00 expecting TRML to fall to within 12 months (a possible -100.00% downside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Tourmaline Bio (NASDAQ:TRML) was provided by Guggenheim, and Tourmaline Bio reiterated their buy rating.

There is no last upgrade for Tourmaline Bio

There is no last downgrade for Tourmaline Bio.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tourmaline Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tourmaline Bio was filed on December 11, 2024 so you should expect the next rating to be made available sometime around December 11, 2025.

While ratings are subjective and will change, the latest Tourmaline Bio (TRML) rating was a reiterated with a price target of $0.00 to $0.00. The current price Tourmaline Bio (TRML) is trading at is $20.78, which is out of the analyst’s predicted range.